戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nsible for the enhanced activation of FII by prothrombinase.
2 ry for efficient catalysis of prothrombin by prothrombinase.
3 ential role in its proteolytic activation by prothrombinase.
4 le for the enhanced procoagulant function of prothrombinase.
5 bin kinetics was determined predominantly by prothrombinase.
6 es the sequential cleavage of prothrombin by prothrombinase.
7 nt docking of Arg(271) at the active site of prothrombinase.
8 ding a recognition site for factor Va within prothrombinase.
9 a detectable way to the enhanced function of prothrombinase.
10 pending on the incorporation of factor Va in prothrombinase.
11 r Va molecule with the various components of prothrombinase.
12 he mechanism of activation of prothrombin by prothrombinase.
13 ffectively unaltered following assembly into prothrombinase.
14 cturally conserved residues in factor Xa and prothrombinase.
15 ane-bound procoagulant complexes, tenase and prothrombinase.
16 or V derivatives to assemble and function in prothrombinase.
17 one of two conformations to a single form of prothrombinase.
18 on of substrate derivatives and product with prothrombinase.
19 serine and inhibit the enzymatic activity of prothrombinase.
20 e of Oregon Green(488) at the active site of prothrombinase.
21 both possible intermediates, or product with prothrombinase.
22 s to bind in a mutually exclusive fashion to prothrombinase.
23 e with the incorporation of prothrombin into prothrombinase.
24 contribution of factor Va to the activity of prothrombinase.
25 nor does it fully explain the specificity of prothrombinase.
26 tor Xa or factor Xa saturably assembled into prothrombinase.
27 iants that could be converted to thrombin by prothrombinase.
28 eceding the scissile bond to the function of prothrombinase.
29 te-mediated protein substrate recognition by prothrombinase.
30 ulation zymogen not known to be activated by prothrombinase.
31 haBFX-2b bind in a mutually exclusive way to prothrombinase.
32 (AP4') was found to be a potent inhibitor of prothrombinase.
33 dent recognition of the protein substrate by prothrombinase.
34 oes not interfere with the assembly of human prothrombinase.
35 on of physiologically relevant inhibition of prothrombinase.
36  Va and/or prothrombin recognition by FXa in prothrombinase.
37 ability to accelerate thrombin production by prothrombinase.
38 rate at which it is converted to thrombin by prothrombinase.
39 on of the rate of cleavage of prothrombin by prothrombinase.
40 FII) is activated to alpha-thrombin (IIa) by prothrombinase.
41  for the strong procoagulant nature of venom prothrombinase.
42 s between the proteinase and cofactor within prothrombinase.
43 te of cleavage of prothrombin at Arg(271) by prothrombinase.
44 335) is required for the optimal activity of prothrombinase.
45 n the timely formation of alpha-thrombin via prothrombinase, a Ca(2+)-dependent complex of factors Va
46 ade, prothrombin is converted to thrombin by prothrombinase, a complex consisting of serine protease
47                                              Prothrombinase activates prothrombin through initial cle
48 se findings suggest that platelet-associated prothrombinase activates prothrombin via an efficient co
49 ested that although the peptide inhibits the prothrombinase activation of the wild type zymogen with
50 rmal affinities and exhibited wild-type-like prothrombinase activities toward prothrombin.
51 sistent with its activity, Alboserpin blocks prothrombinase activity and increases both prothrombin t
52                Peptide 325FIAAE329 inhibited prothrombinase activity and was able to partially decrea
53           Thus, RO318220 appears to increase prothrombinase activity by increasing platelet responsiv
54 re deficient in IQGAP1 demonstrate increased prothrombinase activity compared with wild-type litterma
55      Recent studies have found TFPI inhibits prothrombinase activity during the initiation of coagula
56 centration of 20 microM but had no effect on prothrombinase activity in the presence of excess factor
57                              The exaggerated prothrombinase activity is not associated with enhanced
58                                 However, the prothrombinase activity of rHFVa W(2063, 2064)A was foun
59 tant factor Va are required for half-maximal prothrombinase activity on membranes containing 25% PS.
60                 In addition, measurements of prothrombinase activity on the phospholipid bilayers sho
61  of factor Va (P15H) had no effect on either prothrombinase activity or the ability of the cofactor t
62        A mutant FXa (R165A) that has reduced prothrombinase activity showed both weakened dimerizatio
63                                   Even then, prothrombinase activity was low when compared with activ
64                                              Prothrombinase activity was tested on thrombin- and SFLL
65 252C) potently inhibited plasma clotting and prothrombinase activity with 50% inhibition between 41 a
66                    N42R was found to inhibit prothrombinase activity with an IC50 of approximately 25
67 -704), were found to be potent inhibitors of prothrombinase activity with IC(50) values of approximat
68 I, induces platelet aggregation and platelet prothrombinase activity, and binds uniquely to GPVI in l
69                                Both enhanced prothrombinase activity, and the increase was consistent
70 otently inhibited plasma clotting assays and prothrombinase activity, with 50% inhibition of 12 and 1
71 surface is necessary for the support of full prothrombinase activity.
72  of factor Xa were required for half-maximal prothrombinase activity.
73 ites per platelet, or the 3-fold increase in prothrombinase activity.
74  factor Va and tested them for inhibition of prothrombinase activity.
75 lets with exposed PS had greatly accelerated prothrombinase activity.
76 hosphatidylserine, and FV/Va expression; and prothrombinase activity.
77 n, and calcium ions, myosin greatly enhanced prothrombinase activity.
78                While the enzyme component of prothrombinase alone, factor Xa, bound to a membrane sur
79 n of prothrombin to thrombin is catalyzed by prothrombinase, an enzyme complex composed of the serine
80 ity binding and function of factor Xa within prothrombinase and 2) a binding site for prothrombin is
81  exosite-dependent tethering of substrate to prothrombinase and a relaxation in the constrained prese
82  Va heavy chain to factor Xa activity within prothrombinase and demonstrate that amino acid region 65
83                                         Both prothrombinase and direct binding studies indicated that
84 f factor Xa (FXa) with factor Va (FVa) forms prothrombinase and drives thrombin formation essential f
85 hat is modulated following its assembly into prothrombinase and in turn determines the binding specif
86 al cells can support formation of tenase and prothrombinase and may be a source of activated tissue f
87     Therefore, extended interactions between prothrombinase and substrate regions removed from the cl
88 s a prototypic exosite-directed inhibitor of prothrombinase and suggest that the occlusion of a surfa
89 actadherin was an efficient inhibitor of the prothrombinase and the factor Xase complexes regardless
90 ns and interactions with other components of prothrombinase, and (d) to use the model in order to und
91 x activates ProT with K(m)((app)) similar to prothrombinase, and approximately 85-fold weaker without
92 en activation when both extrinsic tenase and prothrombinase are assembled on an appropriate membrane.
93 es (exosites) rather than the active site of prothrombinase are the principal determinants of binding
94 itor of protein substrate cleavage by bovine prothrombinase as well.
95 croparticles were isolated and quantified by prothrombinase assay at admission, day 3, and day 7.
96 ibited a near normal affinity for fVa in the prothrombinase assay, but a markedly lower affinity for
97 atelet factor 3 availability assay and, in a prothrombinase assay, generated only background levels o
98 d neutrophil-derived CD66b microparticles by prothrombinase assay.
99 elet procoagulant activity was measured in a prothrombinase assay.
100 tent correlated positively with PS-direct in prothrombinase assays and clotting assays, but APC-cofac
101 sphatidylserine (PS), which was confirmed by prothrombinase assays and direct labeling.
102 hese adducts also promote the "PS-dependent" prothrombinase assays, albeit to lower levels.
103 on when Gla-domainless factor Xa was used in prothrombinase assays, whereas sphingosine inhibited act
104 I does not inhibit prothrombin activation by prothrombinase assembled on a two-dimensional lipid bila
105 Extension of these findings to the action of prothrombinase assembled on platelets and endothelial ce
106                                              Prothrombinase assembled on the surface of activated pla
107 a potent inhibitor of thrombin generation by prothrombinase assembled with C6PS, while TFPI-160 and K
108 ant molecules were impaired and the k cat of prothrombinase assembled with factor Va (KF) and factor
109            The second-order rate constant of prothrombinase assembled with factor Va (KF) or factor V
110 400-fold lower than the values obtained with prothrombinase assembled with factor Va (WT).
111  constant for the same reaction catalyzed by prothrombinase assembled with factor Va (WT).
112 n approximately 39% increase in k cat, while prothrombinase assembled with factor Va(4A) exhibited an
113 y employing purified reagents, we found that prothrombinase assembled with factor Va(Delta680-709) di
114 tivation compared to the value obtained with prothrombinase assembled with factor Va(Wt), while proth
115 the activation of prothrombin as compared to prothrombinase assembled with factor Va(Wt).
116                                              Prothrombinase assembled with factor VaFF/MI had decreas
117                            The kcat value of prothrombinase assembled with fV(DeltaB9/Q3) was minimal
118 old compared with the Km value obtained with prothrombinase assembled with fVa(WT).
119                                              Prothrombinase assembled with saturating concentrations
120 ombinase assembled with factor Va(Wt), while prothrombinase assembled with saturating concentrations
121                                              Prothrombinase assembled with saturating concentrations
122 of plasma-derived prothrombin at Arg320 than prothrombinase assembled with saturating concentrations
123 for the overall activation of prothrombin by prothrombinase assembled with saturating concentrations
124                          Kinetic analyses of prothrombinase assembled with the mutant molecules demon
125 phoresis analyzing prothrombin activation by prothrombinase assembled with the mutant molecules revea
126 prothrombin at both Arg(320) and Arg(271) by prothrombinase assembled with the mutant molecules, resu
127                                              Prothrombinase assembled with the quadruple mutant molec
128 via a concerted mechanism through a study of prothrombinase assembly and function on collagen-adhered
129 , HC1-HC5) and tested them for inhibition of prothrombinase assembly and function.
130 ssays, representing inhibition of productive prothrombinase assembly and possible disruption of FXa i
131 y the presumed preeminent role in supporting prothrombinase assembly and thrombin formation.
132 f phospholipid-associated factor Xa prior to prothrombinase assembly and/or by slowing formation of t
133                        TFPI can also inhibit prothrombinase assembly by directly interacting with coa
134       Factor Va is the critical cofactor for prothrombinase assembly required for timely and efficien
135                                              Prothrombinase assembly was demonstrated through visuali
136 argets the early phase of coagulation before prothrombinase assembly.
137  in the regulation of exosite expression and prothrombinase assembly.
138  inhibits initial cleavage of prothrombin by prothrombinase at Arg(320).
139 sites to engage the active site of Xa within prothrombinase at equilibrium.
140  produced after activation of prothrombin by prothrombinase at the site of a vascular injury.
141 ctivation state was measured with a modified prothrombinase-based method.
142 al for coordinated prothrombin activation by prothrombinase because it regulates meizothrombin cleava
143 These data suggest that the peptides inhibit prothrombinase because they interfere with the incorpora
144  the affinity of the wild type substrate for prothrombinase but did not engage the active site of the
145 n (DYDYQ) inhibits prothrombin activation by prothrombinase by inhibiting meizothrombin generation.
146  Similar analyses of the inhibition of human prothrombinase by PD0313052 also identified a slow-onset
147                                Inhibition of prothrombinase by PT557-571 and X415-429 was fVa-indepen
148           We demonstrate rapid inhibition of prothrombinase by TFPIalpha mediated through a high-affi
149 e individual cleavage reactions catalyzed by prothrombinase by using a series of recombinant derivati
150 us, the observed pathway of bond cleavage by prothrombinase can be explained by the kinetic constants
151 er, mutation of Arg(320) to Gln reveals that prothrombinase can cleave prothrombin following Arg side
152 r Va (FVa) serve essential cofactor roles in prothrombinase-catalyzed thrombin generation.
153                                              Prothrombinase catalyzes thrombin formation by the order
154 n activated platelets with factor Va to form prothrombinase completely restores biologic activity.
155  antithrombin inhibition of factor Xa in the prothrombinase complex (factor Va, negatively charged me
156 tivation of prothrombin, as catalyzed by the prothrombinase complex (factor X(a), enzyme; factor V(a)
157  prothrombin recognition by factor Xa in the prothrombinase complex (factor Xa, factor Va, phosphatid
158  The central findings are as follows: 1) the prothrombinase complex (fVa-fXa-Ca(2+)-membrane) accumul
159 nd prothrombin (fII) that may be involved in prothrombinase complex (fXa.factor Va.fII.phospholipids)
160 y sequences in prothrombin (fII) involved in prothrombinase complex (fXa.fVa.fII.phospholipids) assem
161         Thrombin generation assays measuring prothrombinase complex activity demonstrated 1.5-fold hi
162 vivo is the activation of prothrombin by the prothrombinase complex assembled on either an activated
163                                          The prothrombinase complex assembled on the surface of plate
164  323-331 and tested them for their effect on prothrombinase complex assembly and function.
165 iding the necessary procoagulant surface for prothrombinase complex assembly and thrombin generation.
166 PS, with binding to the C1 domain regulating prothrombinase complex assembly.
167 nes support formation of a 60-70% functional prothrombinase complex at saturating factor Va concentra
168 = approximately 40 nm) of a partially active prothrombinase complex between factor Xa and factor Va(2
169                   Based on inhibition of the prothrombinase complex by synthetic peptides, FVa residu
170                                          The prothrombinase complex catalyzes the activation of proth
171 thrombin is proteolytically activated by the prothrombinase complex comprising the serine protease Fa
172                                          The prothrombinase complex consists of the protease factor X
173                             The fully formed prothrombinase complex containing this FVa mutant had fa
174                                          The prothrombinase complex converts prothrombin to alpha-thr
175 a, either in free form or assembled into the prothrombinase complex during the process of prothrombin
176 m spontaneous binding to fXa and unnecessary prothrombinase complex formation, which in turn results
177 avage of prothrombin (ProT) at Arg320 by the prothrombinase complex generates proteolytically active,
178 ts to determine the crystal structure of the prothrombinase complex have been thwarted by the depende
179  and that a cofactor function for fVa in the prothrombinase complex involves inducing a conformationa
180  enzyme activated factor X (FXa) to form the prothrombinase complex is a pivotal initial event in blo
181                                          The prothrombinase complex is comprised of an enzyme, factor
182 ht heparins, indicates that factor Xa in the prothrombinase complex is protected from inhibition by a
183 undation for the establishment of a complete prothrombinase complex model, which might be successful
184 rsion of fII to alpha-thrombin (fIIa) by the prothrombinase complex occurs through 2 parallel pathway
185 pt that protein substrate recognition by the prothrombinase complex of coagulation is achieved by int
186                                       In the prothrombinase complex on the platelet surface, FXa clea
187  blocking phospholipid binding sites for the prothrombinase complex on the surfaces of vesicles and a
188       Pseutarin C is an intrinsically stable prothrombinase complex preassembled in the venom gland o
189           Further studies with the wild-type prothrombinase complex revealed that FXa binds to factor
190 soluble PS to trigger formation of a soluble prothrombinase complex suggests that exposure of PS mole
191 sis, factor Va serves as the cofactor in the prothrombinase complex that results in a 300,000-fold in
192 espect to their ability to assemble into the prothrombinase complex to activate prothrombin and inter
193 ns prothrombin and prethrombin-2 require the prothrombinase complex to be converted to the mature pro
194 lex and then to function as an enzyme in the prothrombinase complex to catalyze the conversion of pro
195 ant substrates; however, its activity in the prothrombinase complex toward most of mutants was severe
196 e-exposed phosphatidylserine (PS) forms the "prothrombinase complex" that is essential for efficient
197 ctly inhibits thrombin generated by FXa/FVa (prothrombinase complex).
198 ng tissue factor VIIa activity, Xa activity, prothrombinase complex, and thrombin generation.
199                                          The prothrombinase complex, composed of the protease factor
200 ts or endothelial cells, factor Xa forms the prothrombinase complex, which is responsible for the pro
201 d Partial Thromboplastin Time'' (aPTT) and ''Prothrombinase complex-induced Clotting Test'' (PiCT) ha
202 t into the architecture and mechanism of the prothrombinase complex-the molecular engine of blood coa
203 ed as an extended FXa binding surface in the prothrombinase complex.
204 ependent prothrombin recognition site in the prothrombinase complex.
205 rsor prothrombin by factor Xa as part of the prothrombinase complex.
206 oth FIXa in the FXase complex and FXa in the prothrombinase complex.
207 ely 3-fold lower catalytic efficiency in the prothrombinase complex.
208 le in FXa recognition of the cofactor in the prothrombinase complex.
209 phatidylserine (PS) regulate activity of the prothrombinase complex.
210 or Va and the Gla domain of factor Xa in the prothrombinase complex.
211 iate interactions between fVa and fII in the prothrombinase complex.
212 ndent recognition sites for factor Xa in the prothrombinase complex.
213 iate interactions between fXa and fII in the prothrombinase complex.
214 ction as zymogens for both factor Xa and the prothrombinase complex.
215  assembly and/or by slowing formation of the prothrombinase complex.
216 e protein substrate recognition by the human prothrombinase complex.
217  and phospholipid membranes, and inhibit the prothrombinase complex.
218 telet membranes regulate the activity of the prothrombinase complex.
219 sequential cleavages at R271 and R320 by the prothrombinase complex.
220 dent recognition site for prothrombin in the prothrombinase complex; however, Lys-96 is a recognition
221 ufficient to produce the fully active human "prothrombinase" complex in solution.
222 ng platelet membranes to form the essential "prothrombinase" complex of blood coagulation.
223 f prothrombin to thrombin is catalyzed by a "prothrombinase" complex, traditionally viewed as factor
224 common" pathway at the level of the FXa/FVa (prothrombinase) complex.
225 ide a surface for assembly of the tenase and prothrombinase complexes required for thrombin generatio
226 egulator of both the intrinsic FXase and the prothrombinase complexes.
227                                              Prothrombinase converts prothrombin to thrombin via clea
228 cket indicate that assembly of the mutant in prothrombinase corrected the impaired binding of these p
229 lpha produces isoform-specific inhibition of prothrombinase during the initiation of coagulation, an
230 r interactions that underlie the assembly of prothrombinase, efficient inhibition of enzyme complex a
231 n of factor Xa was not required for myosin's prothrombinase enhancement.
232  Exosite-dependent binding of prothrombin to prothrombinase facilitates active site docking by Arg(32
233  intrinsic tenase (factor VIIIa/factor IXa), prothrombinase (factor Va/factor Xa), and factor XIa com
234      Because all three protein components of prothrombinase, factors (f) Xa and Va and prothrombin, b
235 irudin, or CD39, or lacking the gene for the prothrombinase, fibrinogen-like protein-2, is anticipate
236 ation expresses phosphatidylserine and binds prothrombinase (FITC Xa.factor Va).
237  milieu already containing factor Xa enables prothrombinase formation with consequent meizothrombin f
238 cells, whereas TFPIalpha dampens the initial prothrombinase formed on the activated platelet surface.
239 ntapeptide with this sequence inhibited both prothrombinase function with an IC(50) of 1.6 microm (wi
240 de the primary biological surface to support prothrombinase function.
241 actor activation and is required for optimum prothrombinase function.
242  exclusive manner and with equal affinity to prothrombinase in a cleavage site-independent way.
243 n, DYDYQ) inhibits prothrombin activation by prothrombinase in a competitive manner with respect to s
244 (2K2F) had impaired cofactor activity within prothrombinase in a system using purified reagents.
245 teolyzed prothrombin species by preassembled prothrombinase in phospholipid-coated glass capillaries
246 ation of the incorporation of factor Va into prothrombinase in vivo by using synthetic peptides that
247                                     A direct prothrombinase inhibition assay, monitoring thrombin gen
248                                              Prothrombinase inhibition by PT473-487 was factor Va (fV
249  the properties of a unique exosite-directed prothrombinase inhibitor.
250 s thrombin is known to bind to an exosite on prothrombinase, initial interactions at an exosite likel
251 ferred pathway for prothrombin activation by prothrombinase involves initial cleavage at Arg(320) to
252                                         When prothrombinase is assembled on synthetic phospholipid ve
253 tivation of prothrombin by surface-localized prothrombinase is clearly mediated by flow-induced dilut
254                                              Prothrombinase is composed of a catalytic subunit, facto
255       The ordered cleavage of prothrombin by prothrombinase is driven by ratcheting of the substrate
256 Tris(+) and that the catalytic efficiency of prothrombinase is enhanced less than 1.5-fold by the spe
257 ontributes to enhanced catalytic efficacy of prothrombinase is not precisely known but is generally a
258 n of all three possible substrate species by prothrombinase is regulated by their ability to bind mem
259                   Factor Va, the cofactor of prothrombinase, is composed of heavy and light chains as
260 ce this modified derivative was assembled in prothrombinase, it functioned in an equivalent manner to
261 hrombin 2 or meizothrombin des-fragment 1 by prothrombinase (K(i)(*) = 0.55 +/- 0.05 nm).
262 complexes of the intrinsic pathway, Xase and prothrombinase, leading to a 20- and 10-fold increase in
263 r rate over preassembled platelet-associated prothrombinase neither potential intermediate, meizothro
264 ation constant (Kd,app) for factor Xa within prothrombinase of approximately 0.5 nM.
265 e for cleavage, yet the sequential action of prothrombinase on Arg(320) followed by Arg(271) is impli
266  of the fVa-dependent site(s) for fXa within prothrombinase on FII, required for efficient initial cl
267               We have examined the action of prothrombinase on full-length prothrombin variants lacki
268 specificity as well as the ordered action of prothrombinase on its compound substrate is regulated by
269 hrombin is produced by the ordered action of prothrombinase on two cleavage sites in prothrombin.
270 te directed inhibitor of human factor Xa and prothrombinase, PD0313052, and identifies structurally c
271                           The enzyme complex prothrombinase plays a pivotal role in fibrin clot devel
272 ork tests whether or not platelet-associated prothrombinase proceeds via a concerted mechanism throug
273       These results suggest that, similar to prothrombinase, proexosite-1 is a cofactor-dependent rec
274 actor Xa with factor Va on membranes to form prothrombinase profoundly increases the rate of the prot
275  rate of 83.9 +/- 3.8 nM/min by about 120 pM prothrombinase, reaching ultimate levels of 851 +/- 53 n
276 ipids, the exact role of the membrane in the prothrombinase reaction has not been fully understood.
277 n are part of a cooperative mechanism within prothrombinase regulating cleavage and activation of pro
278 on of the cofactor molecule, factor Va, into prothrombinase results in a five orders of magnitude inc
279 hus, alphaBFX-2b binding to factor Xa within prothrombinase selectively leads to the inhibition of pr
280             To determine whether, similar to prothrombinase, taipan venom utilizes proexosite-1 on pr
281                   Furthermore, activation by prothrombinase takes place without preference along the
282 actor Xa is the serine protease component of prothrombinase, the enzymatic complex responsible for th
283 vents prothrombin autoactivation and directs prothrombinase to cleave at Arg-271 first.
284 local electrostatic potential then redirects prothrombinase toward Arg-320, leading to thrombin gener
285                        Cleavage of rMZ-II by prothrombinase was completely inhibited by low concentra
286 her structural determinants in factor Xa and prothrombinase was investigated.
287 (S195A), the pathway of FPR-ProT cleavage by prothrombinase was redirected from meizothrombin toward
288 n with the factor Xa variants assembled into prothrombinase was unaltered, whereas the k(cat) was mod
289           In rapid kinetic measurements with prothrombinase, we also show that the zymogen-like form
290 meizothrombin des fragment 1 and thrombin to prothrombinase were comparable with their affinities inf
291 factor Va governing its incorporation within prothrombinase will provide the scaffold for the synthes
292 actor Va binding to any of the components of prothrombinase, will allow for control of the rate of th
293 at HC3 and HC4 are competitive inhibitors of prothrombinase with respect to prothrombin with K(i) val
294 d that AP4' is a noncompetitive inhibitor of prothrombinase with respect to prothrombin, with a K(i)
295 ) was found to be a competitive inhibitor of prothrombinase with respect to prothrombin.
296 trate cleavage by human Xa incorporated into prothrombinase with saturating concentrations of membran
297  of plasma-derived prothrombin activation by prothrombinase, with increasing concentrations of peptid
298 fVa-dependent recognition exosite for fXa in prothrombinase within the amino acid sequence Ser(478)-V
299 7t) inhibits thrombin formation catalyzed by prothrombinase without obscuring the active site of Xa w
300 .93 +/- 0.3 nM/min catalyzed by about 1.3 pM prothrombinase yielding approximately 26 nM thrombin.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top